SCHEMBL1704052

SCHEMBL1704052

Cc1cccc(NC(=O)c2sccc2N(C(=O)O)C(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
RAB9A P51151 3/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
TP53 P04637 3/20 0.48
NPC1 O15118 2/20 0.48
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
MAPT P10636 3/20 0.47
POLB P06746 2/20 0.47
PKM P14618 1/20 0.47
RXFP1 Q9HBX9 2/20 0.47
GAA P10253 1/20 0.47
EDNRB P24530 1/20 0.46
EDNRA P25101 1/20 0.46
NPSR1 Q6W5P4 1/20 0.45
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
KCNK3 O14649 3/20 0.44
KCNK9 Q9NPC2 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703670 0.87 PKM (0.45) RAB9ASMN1; SMN2TP53NPC1MEN1
SCHEMBL1703824 0.86 RAB9A (0.55) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL1704450 0.85 PKM (0.49) ALDH1A1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL1703757 0.78 HPGD (0.48) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL1704322 0.77 MEN1 (0.63) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL5790071 0.77 KIT (0.48) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL1703648 0.76 RAB9A (0.56) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL12496157 0.68 KCNK3 (0.82) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL6660832 0.68 GRM4 (0.60) ALDH1A1RAB9ASMN1; SMN2TP53NPC1
SCHEMBL692386 0.68 HSD17B10 (0.74) ALDH1A1SMN1; SMN2MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441768-A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers Eli Lilly & Co. (US) 2012-04-18 EP disclosed